Research progress on efficacy and influencing factors of postoperative radiotherapy for stage ⅢA(N 2) non-small cell lung cancer / 中华放射肿瘤学杂志

Non-small cell lung cancer(NSCLC) is highly malignant and has poor prognosis, in which stage ⅢA(N 2) NSCLC approximately accounts for 20%. Patients with stage ⅢA(N 2) NSCLC have high heterogeneity and distinct survival difference. Loco-regional recurrence and distant metastasis are the main causes of treatment failure. At present, whether stage ⅢA(N 2) NSCLC patients should receive postoperative radiotherapy(PORT) remains controversial. Such patients still lack high level proof to receive PORT.